Literature DB >> 34076872

Gonadotropin-Releasing Hormone Agonist Versus Recombinant Human Chorionic Gonadotropin Triggering in Fertility Preservation Cycles.

Einat Haikin Herzberger1,2, Sabaa Knaneh3,4, Hadar Amir3,4, Adi Reches3,4, Dalit Ben-Yosef3,4, Yael Kalma3,4, Foad Azem3,4, Nivin Samara3,4.   

Abstract

The purpose of this research is to study the efficacy of GnRH-a versus r-hCG triggering in patients who go through fertility preservation cycles. This retrospective cohort study was performed in a tertiary university-affiliated medical center. It includes 191 patients undergoing fertility preservation cycles between May 2013 and September 2018, in which ovulation was induced by either GnRH-a or r-hCG. Main outcome measures were number and rate of mature oocyte. Among treatment cycles with medical indication, GnRH agonist significantly increases the odds for high mature rate by 3.55 (1.30-9.66), while in treatment cycles with social indication, there is no significant effect of the triggering agent. An advantage for GnRH-a triggering was observed in medically indicated preservation cycles.
© 2021. Society for Reproductive Investigation.

Entities:  

Keywords:  Cancer patients; Elective fertility preservation; Onco-fertility preservation; Oocyte cryopreservation; Ovarian stimulation

Mesh:

Substances:

Year:  2021        PMID: 34076872     DOI: 10.1007/s43032-021-00622-2

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  28 in total

1.  Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.

Authors:  Rachel Babayof; Ehud J Margalioth; Mahmoud Huleihel; Alaa Amash; Edit Zylber-Haran; Michael Gal; Baruch Brooks; Tzvia Mimoni; Talia Eldar-Geva
Journal:  Hum Reprod       Date:  2006-01-26       Impact factor: 6.918

2.  Human chorionic gonadotropin: pharmacokinetics of subcutaneous administration.

Authors:  A Weissman; S Lurie; Y Zalel; R Goldchmit; Z Shoham
Journal:  Gynecol Endocrinol       Date:  1996-08       Impact factor: 2.260

3.  Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support.

Authors:  Lawrence Engmann; Claudio Benadiva
Journal:  Fertil Steril       Date:  2012-01-14       Impact factor: 7.329

4.  Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary.

Authors:  Kutluk Oktay; Brittany E Harvey; Alison W Loren
Journal:  J Oncol Pract       Date:  2018-05-16       Impact factor: 3.840

5.  Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles.

Authors:  Laura Meyer; Lauren A Murphy; Arielle Gumer; David E Reichman; Zev Rosenwaks; Ina N Cholst
Journal:  Fertil Steril       Date:  2015-07-03       Impact factor: 7.329

6.  GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.

Authors:  P Humaidan; H Ejdrup Bredkjaer; L Bungum; M Bungum; M L Grøndahl; L Westergaard; C Yding Andersen
Journal:  Hum Reprod       Date:  2005-03-10       Impact factor: 6.918

Review 7.  GnRHa trigger for final oocyte maturation: is HCG trigger history?

Authors:  Peter Humaidan; Birgit Alsbjerg
Journal:  Reprod Biomed Online       Date:  2014-06-12       Impact factor: 3.828

Review 8.  Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.

Authors:  Annick Delvigne; Serge Rozenberg
Journal:  Hum Reprod Update       Date:  2002 Nov-Dec       Impact factor: 15.610

9.  Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.

Authors:  Daniel Bodri; Juan José Guillén; Anna Galindo; Daniel Mataró; Aïda Pujol; Oriol Coll
Journal:  Fertil Steril       Date:  2008-03-25       Impact factor: 7.329

10.  The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.

Authors:  Lawrence Engmann; Andrea DiLuigi; David Schmidt; John Nulsen; Donald Maier; Claudio Benadiva
Journal:  Fertil Steril       Date:  2007-04-26       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.